BRISTOL MYERS SQUIBB

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Zai Lab announces NRDL inclusion of Augtyro for ROS1+ NSCLC, renewal of Nuzyra for CABP/ABSSSI, and Qinlock for GIST, expanding patient access to innovative treatments in China.

Niven R. Narain emphasizes that AI investments in drug development require robust data and validation. GEN's A-List highlights 10 AI-based drug discovery leaders, including BPGbio, which focuses on cancer energy generation. Other notable companies include Nvidia and Palantir Technologies, though not on the A-List. The list includes specifics on companies like Anima Biotech, Atomwise, and Nimbus Therapeutics, detailing their AI platforms and drug development progress.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

Obe-cel (Aucatzyl) CAR T-cell therapy demonstrated durable remissions in 77% of patients with relapsed or refractory B-cell ALL in the FELIX trial, with 55% achieving complete remission. Median event-free survival was 11.9 months, and overall survival was 15.6 months. Obe-cel showed low severe toxicity, supporting its safety and efficacy.

The European Commission approves BeiGene’s PD-1 inhibitor Tevimbra, in combination with chemotherapy, for first-line treatment of oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. Tevimbra, targeting the PD-1 receptor, enhances T cell activity to attack tumor cells, showing improved median overall survival in Phase III trials.

Since 2017, CAR T cell therapies show effectiveness and safety in clinical trials and real-world settings for certain blood cancers.

Dana-Farber researchers developed a machine learning model using genomic heterogeneity and ploidy to predict resistance to anti-PD-1 therapy in metastatic melanoma, validated in four cohorts. The model suggests 43% of predicted resistant patients respond to combination therapy, potentially guiding treatment choices.

Nivolumab plus ipilimumab significantly improved progression-free survival over chemotherapy in untreated MSI-H or dMMR metastatic colorectal cancer patients, with 72% vs. 14% 24-month survival rates and fewer severe adverse events.